Prognosticul materno-fetal şi managementul bolilor inflamatorii intestinale în sarcină

 Maternal-fetal outcome and management in inflammatory bowel disease during pregnancy

First published: 07 mai 2018

Editorial Group: MEDICHUB MEDIA

DOI: 10.26416/Peri.2.1.2018.1654


Inflammatory bowel diseases (IBD) – ulcerative colitis, Chron disease and indeterminate colitis – affect mainly women at childbearing age, resulting in a challenge for obtaining a pregnancy. The aim of the therapeutic management is to obtain a good control of the disease before conception, with a combined medical surveillance throughout pregnancy (gastroenterological, obstetrical and neonatal). The advances in IBD treatment during pregnancy and lactation have resulted in a better maternal-fetal outcome. Weak control of the disease correlates with specific complications, such as misscariage, premature birth, insufficient intrauterine growth, preeclampsia, increased number of caesarean sections, low Apgar score at birth. The association between inflammatory intestinal disease, its treatment and the occurrence of fetal malformations remains controversial, although numerous studies have been conducted to verify this aspect. The introduction of biological therapy in the treatment of inflammatory bowel disease in pregnancy led to a better control of the disease, but brought new challenges for obstetricians and neonatologists. 

pregnancy, treatment, inflammatory bowel disease, adverse outcome


Bolile inflamatorii intestinale (rectocolita ulcerohemoragică, boala Chron, colite neprecizate) afectează femeile tinere de vârstă fertilă, ducând la o provocare a obţinerii unei sarcini sănătoase. Elementul central al managementului acestui tip de patologie în sarcină este obţinerea unui bun control al bolii înainte de concepţie şi planificarea atentă a sarcinii sub stricta supraveghere gastroenterolog-obstetrician-neonatolog. Continuarea tratamentului bolii pe parcursul sarcinii a dus la optimizarea outcome-ului materno-fetal. Controlul slab al bolii se corelează cu complicaţii specifice, precum: avorturi recurente, naştere prematură, restricţie de creştere intrauterină, preeclampsie, creşterea numărului de naşteri prin operaţie cezariană, scor Apgar scăzut la naştere. Asocierea dintre boala inflamatorie intestinală, tratamentul acesteia şi apariţia de malformaţii fetale rămâne controversată, deşi au fost derulate numeroase studii pentru a verifica acest aspect. Introducerea terapiei biologice în tratamentul bolii inflamatorii intestinale în sarcină a dus la un control mai bun al bolii de bază, dar a adus şi noi provocări pentru obstetricieni şi neonatologi.


Inflammatory bowel disease (IBD) affects mainly women at childbearing age, resulting in a challenge for obtaining a pregnancy. This issue is being discussed with interest by international organizations. The European Crohn’s and Colitis Organization (ECCO) developed the European Consensus on reproduction in inflammatory bowel disease, first in a meeting held in Prague in February 2010(1), and updated the statements in the second European evidence-based consensus on reproduction and pregnancy in inflammatory bowel disease, in 2015(2). The ECCO statements are based on an international consensus on guidelines in fertility, pregnancy and delivery, maternal-fetal outcome and lactation in patients with IBD(2). The existing data of the IBD impact on the reproduction function are still inconsistent, and the potential correlation between IBD, its treatment during pregnancy and maternal-fetal complications – such as miscarriage, preterm delivery, insufficient fetal growth, preeclampsia, low Apgar score and fetal malformations – are still topics of medical interest.

Fertility and IBD

Crohn’s disease (CD) and ulcerative colitis (UC) have an increasing incidence and prevalence among young fertile patients(3). Getting a pregnancy in this category of patients is often a sensitive issue, due to concerns about the impact that IBD has on fertility and pregnancy, with influence on the maternal-fetal outcome, on the timing and mode of delivery and in the postpartum and lactation period. Regarding the subject of fertility, a new category of infertility – dubbed “voluntary infertility” – has appeared. This so-called “voluntary childlessness” refers to the fear of procreation, the fear of transmitting the disease, the fear of fetal malformation due to the IBD treatment(4). However, it is important to note that all studies published so far on this topic concluded that the fertility rate in IBD patients is the same as in general population(5,6). So, the fact that patients with IBD have less children than general population is related to voluntary childlessness(4,7). An active disease can reduce the fertility directly by inducing inflammation in the fallopian tubes and ovaries and by perianal disease associated with dyspareunia, or indirectly by adhesion formation post-surgical approach(8). Şenateş and Fréour have studied the relation between ovarian function and IBD, and concluded that there is a reduction in the level of AMH at women over the age of 30 and with active disease(9,10). ECCO concluded that there is no evidence that controlled IBD reduces fertility, but active disease and the fear of childbearing being ill impacts negativly the fertility rate(2). When the active disease needs pelvic surgery, the rate of fertility may be decresead due to the appereance of pelvic adhesions, altering the tubes motility and ovarian ovulation process. Moreover, pelvic surgery may affect the sexual function due to perianal disease, dispareunia and lowering self-esteem(11,12). Severe cases complicated with the need for an ileoanal pouch or an ileorectal anastomosis may be associated with subfertility(13,14). Searching the literature, we found some studies that indicate that infertility rates after laparoscopic ileal pouch-anal anastomosis surgery are lower than those seen after open ileal pouch-anal anastomosis surgery, which may be due to the lower adhesion formation after laparoscopic approach(15). Taking into account the abovementioned, it is indicated that young women who have not conceived avoid pelvic surgery until having a baby.

IBD and maternal-fetal outcome

The maternal-fetal outcome in patients with IBD is a provocative topic. There are both concerns about the impact that a pregnancy can have on the IBD evolution, and about the IBD itself on the fetal development and outcome and maternal health. So, the impact of IBD on pregnancy depends on disease activity at conception(16). When a pregnancy is obtained in a moment of quiescent disease, the patient has similar risks to those of the general population regarding miscarriage, pregnancy-related complications and adverse fetal and neonatal outcomes, and the risk of relapse is the same as in non-pregnant women(2,17). Regarding the impact that pregnancy has on the disease course, studies have showed that when pregnancy occurs during a period of disease remision, the rate of relapse of Crohn’s disease is similar to that of non-pregnant women (i.e., a third of patients)(18), and in ulcerative colitis this risk is higher(19). ECCO states that conception occurring at a time of active disease increases the risk of persistent activity during pregnancy, and pregnancy may influence the course of inflammatory bowel disease(2). Pregnancy itself has an impact on the immune system. Studies showed that pregnancy may be favorable to Crohn’s disease, but can worsen the evolution of ulcerative colitis(20). The disease activity at conception has been associated with adverse perinatal outcomes such as preterm births, low birth weight (LBW), eclampsia, preeclampsia, placenta praevia, abruptio placentae, or prolonged premature rupture of membranes, miscarriage and an increased C-section rate. When having a comparison between CD and UC, the data from literature conclude that pregnant women with CD have more risk than those with UC(18). Although data regarding the effect of disease activity on pregnancy outcomes remain inconsistent, the medical advise is to conceive while the disease is in remission and to continue the medication throughout the pregnancy, in order to maintain the remission and avoid worse pregnancy outcomes(21). Regarding the risk of giving birth to a child with severe malformations, the studies are inconcludent. As a conclusion, it is of the utmost importance to conceive while IBD is in remision.

Delivery and postpartum in IBD

The delivery mode in IBD pregnant women is the obstetrician choice in the majority of cases, but C-section must be indicated when perianal disease is active or there is active rectal involvement(2). Multidisciplinary aproach regarding these cases (gastroenterology, general surgery, neonatology, obstetrics) should create a balanced view of the best choice of treatment, taking into account the posible consequences of a postpartum sphincter/pelvic floor impairment. Vaginal delivery can be tempted when there is no active perianal disease, but with the precau­tion of avoiding episiotomy(22). Hatch et al. published a large retrospective review about the delivery mode on patients with IBD and concluded that active perianal disease corelates with severe perineum laceration(23). Ileal pouch-anal anastomosis is considered a relative indication for C-section, but it is important to know that it is deemed borderline incontinence, so the risk of an impairment on pelvic floor with fecal incontinence may alter the quality of life in these patients(24).

The postpartum period is like a hormonal storm and may influence the disease flares. Studies showed that there is no risk for increased flares when maintaing the therapy during postpartum in CD, but UC can be complicated with a flare even being under treatment in postpartum(19).

A child from a family with IBD has a higher risk to develop IBD when compared to general population. The risk is higher in CD if both parents are affected(2). The overall risk to develop IBD for a child with one parent affected is about 2-13 times higher than in the general population(25).

Management of IBD during pregnancy

An adequate therapeutic control of the disease during pregnancy and puerperium will reduce both maternal-fetal and neonatal complication rates. It is important to maintain the remission during pregnancy and postpartum by having a strict adherence to the treatment. IBD medication can be used safely in pregnancy, except for thalidomide and methotrexate, which are teratogenetic. The aminosalicylates (sulfasalazine, mesalamines) are of category B in the FDA classification. Although mesalamine can be identified in the cord blood, there were reported no  abnormalities in fetuses resulted from mothers with intake of these drugs during pregnancy(26). Delayed-release mesalamine is considered of category C. The studies published did not demonstrate an increased risk for misscariage, but have demonstrated a higher rate of premature birth, stillbirth and low birthweight; however, the confounding factor of active disease is dif­ficult to delineate(26-28). Sulfasalazine is currently included in category B and, because it interferes with folate absorption, the supplementation is recommended, in order to avoid defects of the fetal neural tube(29). Rahimi et al. elaborated a meta-analysis and concluded that mesalamine and sulfasalazine are not associated with an increased risk for fetal malformations, premature birth, miscarriage or low birth weight(26).

Thiopurines (6-mercaptopurine, azathioprine) are classified as category D drugs in pregnancy, and are purine analogues which interfere with the synthesis of DNA, crosses the placenta and can be identified in fetal blood(30). The prospective PIANO (Pregnancy in IBD Neonatal Outcomes) Registry shows that the use of thiopurines does not lead to worse fetal outcomes(31). Due to its passing through the placenta and the insufficient safety data, it shouldn’t be used during pregnancy.

All corticosteroids cross the placenta and are converted by the placental 11-hydroxygenase in less active metabolites, so the fetal risks are decreased. The reports existing about corticosteroids in the first trimester are inconclusive: some studies reported an increased risk on orofacial malformations (cleft lip/palate), other studies disprove these findings, and other reports sugest that there is a risk for developing neonatal adrenal suppression when corticosteroids are used late in pregnancy(18,32,33). In addition to fetal risks, it must be taken into consideration the possible maternal complications that may occur due to corticosteroids intake, such as such as hypertension, diabetes and preeclampsia(34).

The biological therapy include anti-tumor necrosis factor α (anti-TNF) derivates, such as infliximab, adalilumab and certolizumab. These molecules are IgG-like immunoglobuline molecules that differ in their biochemical structure, half-life and transplacental passage(35). Unfortunately, there are few studies on the effects of biological therapy on pregnancy and fetus due to ethical causes. Searching the data from literature and from registries, we can conclude that the biological therapy is relatively safe when the medication is chosen according to the half-life, depending on the placental passage, and the possible adverse effects on the fetus and the newborn are known(37). Searching the persistence of TNFα inhibitors in the serum of the infants, studies have shown a persistence of 3-6 months for infliximab and for at least 11 weeks postpartum for adalimumab(36,37). Because TNF plays an important role in immunity against bacterial and viral infections, and pregnancy itself is a state of immunosuppression, this association represents a high risk for opportunistic infection in neonatal life(36). When compared with adalilumab and certolizumab, infliximab has the higher placental passage, and it must be stopped before 28 weeks of gestation.

The PIANO study showed no increased risk for maternal-fetal outcome when using adalilumab during pregnancy(31). Although intrauterine exposure to anti-TNF agents seems to have no risk on fetal development, the effects on the fetal imune system remain uncertain. Certolizumab pegol is a different IgG molecule, with dif­ferent placental passage mechanism, having a low rate of transfer during the third trimester. It is a molecule that seems safer to use during late pregnancy(38). Unfortunately, data regarding the safety on using certolizumab during pregnancy are still limited.


Despite the lack of data, we should always keep in mind that the maternal-fetal risks related to an active maternal disease are higher compared to the risk of using therapy to control the disease. The biological therapy is a promising therapy, but it must be used properly in cases of steroid-refractory diseaseas, or multi-drug resistance disease. Adalilumab and infliximab should be interrupted before the third trimester, while certolizumab pegol seems to be safer to use even in the third trimester. Counseling during pregnancy is a must, because a interruption of therapy can induce a severe flare, with negative impact on the maternal-fetal outcome. The most frequent reason for non-compliance during pregnancy is the fear of adverse effects of medication on the fetus(39). Adequate treatment should be offered to those patients who wish to conceive, with the aim of reducing the risk of flares during pregnancy. Active disease and acute flares can compromise the maternal-fetal outcome in patients with IBD.  

Conflict of interests: The authors declare no conflict of interests.


1. Van der Woude CJ, Kolacek S, Dotan I, et al. European Crohns Colitis Org E. European evidenced-based consensus on reproduction in inflammatory bowel disease. Journal of Crohns & Colitis. 2010; 4:493–510.
2. Van der Woude CJ et al. The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis. 2015; 107–124 doi:10.1093/ecco-jcc/jju006 ECCO Guidelines/Consensus Paper
3. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006; 101: 1274–82.
4. Marri SR, Ahn C, Buchman AL. Voluntary childlessness is increased in women with inflammatory bowel disease. Inflamm Bowel Dis. 2007; May; 13(5):591-9DOI:10.1002/ibd.20082.
5. Hudson M, Flett G, Sinclair TS, Brunt PW, Templeton A, Mowat NA. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet. 1997; 58:229–37.
6. Mañosa M, Navarro-Llavat M, Marín L, Zabana Y, Cabré E, Domènech E. Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey. Scand J Gastroenterol. 2013; 48:427–32.
7. Selinger CP, Eaden J, Selby W, et al. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis. 2012; 7:e206–13.
8. Ørding Olsen K, Juul S, Berndtsson I, Oresland T, Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology. 2002; 122:15–9.
9. Şenateş E, Çolak Y, Erdem ED, et al. Serum anti-müllerian hormone levels are lower in reproductive-age women with Crohn’s disease compared to healthy control women. J Crohns Colitis. 2013; 7 :e29–34.
10. Fréour T, Miossec C, Bach-Ngohou K, et al. Ovarian reserve in young women of reproductive age with Crohn’s disease. Inflamm Bowel Dis. 2012; 18:1515–22.
11. Johnson E, Carlsen E, Nazir M, Nygaard K. Morbidity and functional outcome after restorative proctocolectomy for ulcerative colitis. Eur J Surg. 2001; 167:40–5.
12. Davies RJ, O’Connor BI, Victor C, MacRae HM, Cohen Z, McLeod RS. A prospective evaluation of sexual function and quality of life after ileal pouch-anal anastomosis. Dis Colon Rectum. 2008; 51:1032–5.
13. Lepistö A, Sarna S, Tiitinen A, Järvinen HJ. Female fertility and childbirth after ileal pouch-anal anastomosis for ulcerative colitis. Br J Surg. 2007; 94:478–82.
14. Johnson P, Richard C, Ravid A, et al. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2004; 47:1119–26.
15. Hull TL, Joyce MR, Geisler DP, Coffey JC. Adhesions after laparoscopic and open ileal pouch-anal anastomosis surgery for ulcerative colitis. Br J Surg. 2012; 99:270–5.
16. Beaulieu DB, Kane S. Inflammatory bowel disease in pregnancy. World J Gastroenterol. 2011; June 14; 17(22): 2696-2701.
17. Bush MC, Patel S, Lapinski RH, Stone JL. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med. 2004; 15: 237-241.
18. Reddy D, Murphy SJ, Kane SV, Present DH, Kornbluth AA. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008; 103:1203–1209.
19. Pedersen N, Bortoli A, Duricova D, et al. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther. 2013; 38:501–12.
20. Piccinni MP, Scaletti C, Maggi E, Romagnani S. Role of hormone controlled Th1-and Th2-type cytokines in successful pregnancy. J Neuroimmunol. 2000; 109:30–3.
21. Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol. 1984; 6(3):211-216.
22. Brandt LJ, Estabrook SG, Reinus JF. Results of a survey to evaluate whether vaginal delivery and episiotomy lead to perineal involvement in women with Crohn’s disease. Am J Gastroenterol. 1995; 90:1918–22.
23. Hatch Q, Champagne BJ, Maykel JA, et al. Crohn’s disease and pregnancy: the impact of perianal disease on delivery methods and complications. Dis Colon Rectum. 2014; 57:174–8.
24. Ravid A, Richard CS, Spencer LM, et al. Pregnancy, delivery, and pouch function after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2002; 45:1283–8.
25. Bennett RA, Rubin PH, Present DH. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology. 1991; 100:1638–43.
26. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod toxicol. 2008; 25(2):271-275.
27. Norgard B, Fonager K, Pedersen L, Jacobsen BA, Sorensen HT. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut. 2003; 52:243–7.
28. Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007; 56:830–7.
29. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006; 131(1):283-311.
30. De Boer NKH, Jarbandhan SVA, de Graaf P, Mulder CJJ, van Elurg RM, van Bodegraven AA. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol. 2006; 101:1390–2.
31. Mahadevan U, Martin CF, Sandler RS, et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy [abstract 865]. Gastroenterology. 2012; 142(5 suppl 1):S-149.
32. Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol. 2007; 197:683–4.
33. Homar V, Grosek S, Battelino T. High-dose methylprednisolone in a pregnant woman with Crohn’s disease and adrenal suppression in her newborn. Neonatology. 2008; 94:306–9.
34. Martel MJ, Rey E, Beauchesne MF, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ. 2005; 330:230–3.
35. Suzuki T, Ishii-Watabe A, Tada M, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol. 2010; 184:1968–76.
36. Boiangiu A, Bălănescu A, Vlădăreanu R. The use of biological drugs in autoimmune diseases during pregnancy and lactation. 2017; DOI: 10.26416/Peri.1.4.2017.1427.
37. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013; 11:286–92.
38. Mahadevan U, Abreu MT. Certolizumab use in pregnancy: low levels detected in cord blood. Gastroenterology. 2009; 136:A146–A.
39. Mountifield RE, Prosser R, Bampton P, Muller K, Andrews JM. Pregnancy and IBD treatment: this challenging interplay from a patients’ perspective. J Crohns Colitis. 2010; 4:176–82.

Articole din ediţiile anterioare

ORIGINAL PAPER | Ediţia 2 1 / 2017

Efectele expunerii la alcool asupra ficatului  şi miocardului fetal

Daniela Pintican, Ștefan Strilciuc, Dan Mihu

Consumul de alcool în timpul sarcinii expune fătul la o serie de modificări fizice şi neurocomportamentale, printre care şi sindromul alcoolic feta...

16 iunie 2017
ORIGINAL PAPER | Ediţia 2 2 / 2018

Influenţa fumatului în sarcină asupra greutăţii fetale – studiu retrospectiv

Dr. Andrei Vlad  Trăistaru, Prof. Dr. Radu Vlădăreanu, Simona Vlădăreanu

Datele actuale legate de efectul fumatului asupra greutăţii fetale arată că, în funcţie de numărul de ţigarete consumate pe zi şi momentul expuneri...

23 iunie 2018
OBSTETRICS | Ediţia 3 1 / 2017

Nutriţia în sarcină

Alexandra Bruja

În sarcină, o dietă alimentară echilibrată în nutrienţi se asociază cu creşterea ratei de supravieţuire perinatale, creşterea greutăţii fetale la n...

30 octombrie 2017
CASE REPORT | Ediţia 4 1 / 2017

Malformaţii multiple la un prematur provenit din sarcină gemelară: sindrom Peters Plus? Prezentare de caz

Diana Costache, Iulia Petrescu, Ana Maria Măreşescu, Lavinia Duică, Roxana Nicolescu, Mihaela Bălgrădean, Simona Vlădăreanu

În cazul asocierii de malformaţii la acelaşi pacient, clinicianul va suspecta întotdeauna un sindrom ce va trebui confirmat prin metodele diagnosti...

24 decembrie 2017